SymBio Pharmaceuticals Limited Logo

SymBio Pharmaceuticals Limited

Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.

4582 | T

Overview

Corporate Details

ISIN(s):
JP3383050006
LEI:
Country:
Japan
Address:
港区虎ノ門四丁目1番28号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company dedicated to addressing unmet medical needs. Its core business model involves acquiring the rights to develop and commercialize promising new drug candidates from global bio-ventures and pharmaceutical firms. The company focuses on therapeutic areas including oncology, hematology, autoimmune diseases, and infectious diseases. SymBio aims to deliver innovative treatments to patients, particularly for conditions underserved by the broader industry, with a primary market focus on Japan and the Asia-Pacific region.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-05 02:11
Registration Form
確認書
Japanese 9.0 KB
2025-08-04 09:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 281.2 KB
2025-08-04 09:04
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 356.9 KB
2025-07-31 08:37
Registration Form
訂正有価証券届出書(参照方式)
Japanese 276.5 KB
2025-07-22 09:24
Registration Form
有価証券届出書(参照方式)
Japanese 524.8 KB
2025-04-21 03:23
Share Issue/Capital Change
訂正臨時報告書
Japanese 36.1 KB
2025-04-18 09:38
Share Issue/Capital Change
訂正臨時報告書
Japanese 40.4 KB
2025-03-26 05:29
Registration Form
訂正有価証券届出書(参照方式)
Japanese 207.2 KB
2025-03-26 05:04
Post-Annual General Meeting Information
臨時報告書
Japanese 26.2 KB
2025-03-25 07:35
Share Issue/Capital Change
臨時報告書
Japanese 44.1 KB
2025-03-25 07:34
Registration Form
訂正有価証券届出書(参照方式)
Japanese 312.0 KB
2025-03-25 07:32
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.9 KB
2025-03-25 07:31
Registration Form
確認書
Japanese 9.0 KB
2025-03-25 07:30
Annual Report
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 1.9 MB
2025-02-20 08:20
Registration Form
訂正有価証券届出書(参照方式)
Japanese 241.9 KB

Automate Your Workflow. Get a real-time feed of all SymBio Pharmaceuticals Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SymBio Pharmaceuticals Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SymBio Pharmaceuticals Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.